drugset / Trial / NCT00391404

Fosamax for Childhood Cancer Survivors

NCT00391404

Phase 3 Unknown 100 enrolled Chinese University of Hong Kong
RandomizedParallel-groupOpen-labelTreatment

Summary

Survivors of childhood cancers face a variety of long-term problems. The investigators' recent study found that osteoporosis and osteopenia were common among these patients. The factors leading to, as well as the best treatment option for, this morbidity are unclear. Bisphosphonates are currently the standard therapy for osteoporosis in the elderly. However, the efficacy and safety of bisphosphonates for treating osteoporosis in long-term cancer survivors have not been tested. The investigators hypothesize that alendronate, an orally active bisphosphonate, is efficacious and safe in the treatment of osteoporosis in these patients.

Timeline

Start
2006-05
Primary completion
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alendronic Acid Small molecule 70 mg Oral

Indications